2018年12月14日
Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer
Oncotarget
- 巻
- 9
- 号
- 98
- 開始ページ
- 37216
- 終了ページ
- 37228
- 記述言語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.18632/oncotarget.26469
- 出版者・発行元
- Impact Journals, LLC
© Shibata et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The enhanced expression of the Y-box binding protein YBX1 is consistently correlated with poor outcomes or reduced survival of breast cancer patients. However, the mechanism underlying the association between increased YBX1 expression and poor outcomes has yet to be revealed. We searched a database for the top 500 genes that are positively or negatively correlated with YBX1 and with ESR1 in breast cancer patients. We further examined the association between YBX1-correlated genes and breast cancer outcomes in patients at Kyushu University Hospital. More than 60% of genes that are positively correlated with YBX1 are also negatively correlated with ESR1. The enhanced expression levels of the top 20 positively correlated genes mostly predict negative outcomes, while the enhanced expression levels of the top 20 negatively correlated genes mostly predict positive outcomes. Furthermore, in breast cancer patients at Kyushu University Hospital, the expression levels of YBX1 and YBX1-positively correlated genes were significantly higher and the expression levels of genes negatively correlated with YBX1 were significantly lower in patients who relapsed after their primary surgery than in those who did not relapse. The expression of YBX1 together with the expression of its positively or negatively correlated genes may help to predict outcomes as well as resistance to endocrine therapies in breast cancer patients. Determining the expression of YBX1 and its closely correlated genes will contribute to the development of precision therapeutics for breast cancer.
- リンク情報
- ID情報
-
- DOI : 10.18632/oncotarget.26469
- eISSN : 1949-2553
- PubMed ID : 30647855
- SCOPUS ID : 85058496526